Topics

Companies Related to "Xencor begins phase trial XmAb23104 advanced solid tumors" [Most Relevant Company Matches] RSS

01:39 EST 18th January 2020 | BioPortfolio

Here are the most relevant search results for "Xencor begins phase trial XmAb23104 advanced solid tumors" found in our extensive corporate database of over 50,000 company records.

Showing "Xencor begins phase trial XmAb23104 advanced solid tumors" Companies 1–25 of 4,000+

Extremely Relevant

Organovo Holdings, Inc. and Tarveda Therapeutics, Inc.

Tarveda Therapeutics is a clinical stage biopharmaceutical company developing a new class of potent and selective precision oncology medicines, which it refers to as Pentarin® miniature drug conjugates, for the treatment of patients with various solid tumor malignancies. Tarveda currently has two Pentarin miniature drug conjugates in clinical trials. Its first clinical program, PEN-866, is its...


Xencor, Inc.

Xencor, Inc. engineers superior biotherapeutics using its proprietary Protein Design Automation® technology platform, and is a leader in the field of antibody engineering to significantly improve antibody half-life, immune-regulatory function and potency. The company is advancing multiple XmAb® antibody drug candidates into the clinic, including XmAb...

Relevant

Direct Therapeutics, Inc.

Direct Therapeutics, Inc. is a development-stage pharmaceutical company using its patented Solvent-Facilitated Perfusion technology to create new drugs for the localized and regional treatment of solid-tumor cancers. Our products are designed for direct injection to target tissue with minimal invasion of healthy tissue. They contain active ingredients in organic solvent vehicles that facilitate th...


Grid Therapeutics, LLC

Grid Therapeutics is a biotech company based on the innovative platform for discovering and isolating human derived antibodies. Dr Edward F. Patz, Jr, is the co-founder and CEO of Grid, located in Durham, North Carolina. The lead antibody was discovered in exceptional outcome early stage lung cancer patients who did not progress to develop metastasis. ...

Protox Therapeutics Inc.

Protox Therapeutics is a product-focused development-stage company and a leader in advancing novel, targeted protein toxin therapeutics for the treatment of cancer and other proliferative diseases. Through the company’s INxin™ and PORxin™ technology platforms, therapeutic candidates are generated by engineering the naturally occurring toxins, Pseudomonas exotoxin and proaerolysin. These drug...

Xencor Incorporated

Xencor™ is a biotechnology company that is commercializing Protein Design Automation™ (PDA), a proprietary research platform for protein design. PDA builds on recent groundbreaking advances in computer capabilities and computational chemistry methods to design protein and peptide variants, as well as completely unique protein sequences. PDA produces novel proteins that preserve target functio...

Corvas International Incorporated

Corvas International, Inc. is a biopharmaceutical company focused on development of a new generation of drugs that address today's largest medical markets, cardiovascular disease and cancer, based on our expertise in vascular biology and protease modulation. We have a strategic alliance with Pfizer Inc for the development and commercialization of our novel anti-inflammatory agent (rNIF or UK-279,2...

WILEX AG

WILEX is a biopharmaceutical company developing novel cancer therapies for the treatment of various tumors including renal and breast cancer. Therapies are based upon biologic targets directly connected to cancer progression and pathogenesis in order to provide effective and well-tolerated treatment and enhance patients' quality of life.The company has a portfolio of cancer drug candidates ranging...

Siamab Therapeutics, Inc.

Siamab Therapeutics, Inc. is a biopharmaceutical company developing novel cancer immunotherapies targeting cancer-specific carbohydrate antigens seen in multiple solid tumors. Siamab has developed a platform that enables the rapid discovery and development of therapeutic antibodies that bind with unprecedented specificity and affinity to this novel class o...

Torque Therapeutics

Torque is a clinical-stage immuno-oncology company developing Deep-Primed™ T cell immunotherapy to direct immune power deep within the tumor microenvironment. Torque’s first product candidate—TRQ-1501 (Deep IL-15 Primed T cells)—is in a Phase 1/2 clinical trial for solid tumors and hematologic cancers. The company is based in Cambridge, Massachusetts. To learn more about Torqu...

Iconic Therapeutics

Iconic Therapeutics is a clinical stage biopharmaceutical company dedicated to translating an understanding of the role of Tissue Factor biology to new therapeutics for retinal disease and cancer. The company’s lead product candidate, ICON-1, is a novel fusion protein designed to address the basis of vision loss in AMD. By targeting inflammation and a...

Oncternal Therapeutics, Inc.

Oncternal Therapeutics is a clinical-stage biopharmaceutical company focused on developing a diverse pipeline of product candidates for the treatment of cancers with critical unmet medical need. Oncternal focuses drug development on promising yet untapped biological pathways implicated in cancer generation and progression. The pipeline includes its lead clinical program, cirmtuzumab, a monoclonal...

Syros Pharmaceuticals, Inc.

Syros Pharmaceuticals is pioneering the understanding of the non-coding region of the genome to advance a new wave of medicines that control expression of disease-driving genes. Syros has built a proprietary platform that is designed to systematically and efficiently analyze this unexploited region of DNA in human disease tissue to identify and drug novel ...

Quantum Clinical Research

Global Clinical Trial/Project Management Therapeutic Specialization Phase I Clinical Trial Mgmt Capabilities Phase II-III Capabilities Phase IIIb –IV Capabilities Post marketing Surveillance Treatment IND & Compassionate Use Regulatory Operations & QA Capabilities Worldwide Drug Safety Clinical Trial Monitoring CRA/Monitor Training Select Biometrics Capabilities

Iconic Therapeutics, Inc.

Iconic Therapeutics is a clinical stage biopharmaceutical company dedicated to translating an understanding of the role of Tissue Factor biology to new therapeutics for retinal disease and cancer. The company’s lead product candidate, ICON-1, is a novel fusion protein designed to address the basis of vision loss in AMD. By targeting inflammation and a...

Tyrogenex

Tyrogenex is developing X-82, as a targeted therapeutic for ophthalmological diseases and solid tumors. Preliminary data from a phase 1/2 pilot study show that X-82 is well tolerated and did not exhibit any dose-limiting toxicity during the study.

Threshold Pharmaceuticals, Inc.

Threshold is a biotechnology company focused on the discovery and development of drugs targeting Tumor Hypoxia, the low oxygen condition found in microenvironments of most solid tumors. This approach offers broad potential to treat most solid tumors. By selectively targeting tumor cells, we are building a pipeline of drugs that hold promise to be more effe...

SGX Pharmaceuticals

SGX Pharmaceuticals (formerly Structural GenomiX) is a biotechnology company focused on the discovery, development and commercialization of innovative cancer therapeutics.We are developing Troxatyl™, a novel compound that is currently in a pivotal Phase II/III clinical trial for the third-line treatment of Acute Myelogenous Leukemia (AML). We also plan to develop Troxatyl in combination with Ara...

ViRexx Medical

ViRexx Medical Corp. is an Edmonton, Alberta based biotechnology company focused on the development of novel therapeutic products for the treatment of cancer and chronic viral infections. ViRexx's most advanced programs include drug candidates for the treatment of ovarian cancer, chronic Hepatitis B & C and solid tumors. The lead product from the AIT™ platform is OvaRex® MAb, a therapy for lat...

CardioVascular BioTherapeutics, Inc.

CVBT is a biopharmaceutical company developing drug candidates with FGF-1 as its active pharmaceutical ingredient (API) for diseases characterized by inadequate blood flow to a tissue or organ. The company has FDA-authorization for a Phase II trial to treat severe Coronary Heart Disease (CVBT-141H) and a Phase I trial to treat Peripheral Arterial Disease (CVBT-141C). A Phase III trial to treat der...

Xcovery Holdings, Inc.

Xcovery is a biopharmaceutical company working to improve the lives of patients with cancer by discovering medicines to fight advanced tumors. Xcovery is developing a pipeline of oncology therapies to target a wide range of advanced tumors. For more information, visit www.xcovery.com.

TKL Research, Inc.

TKL Research is a full-service, international CRO offering complete Phase 1-4 clinical trial services, often in enrollment-driven therapeutic areas. The company has a solid reputation for reducing clinical trial timelines by taking responsibility for enrollment and site selection. TKL’s experience began in dermatology and now includes allergy/respirat...

Immunomedics, Inc.

Immunomedics (the “Company”) is a clinical-stage biopharmaceutical company developing monoclonal antibody-based products for the targeted treatment of cancer, autoimmune disorders and other serious diseases. Immunomedics’ advanced proprietary technologies allow the Company to create humanized antibodies that can be used either alone in unlabeled ...

Arch Oncology, Inc.

Arch Oncology, Inc. is a privately-held, clinical-stage immuno-oncology company focused on the discovery and development of best-in-class antibody therapies for the treatment of patients with cancer. The Company’s next-generation anti-CD47 antibodies are highly differentiated, with the potential to improve upon the safety and efficacy profile relative...

OncoMed Pharmaceuticals Inc.

OncoMed Pharmaceuticals is pioneering the development of novel therapeutics that target a new class of solid tumor cells, known as "cancer stem cells". The company's technology is based on a recent discovery by its co-founders that cancer stem cells are uniquely responsible for the growth and proliferation of tumors. We are leveraging our advanced understanding of cancer stem cells to identify the...


More From BioPortfolio on "Xencor begins phase trial XmAb23104 advanced solid tumors"

Quick Search

Corporate Database Quicklinks